Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1)

Pedro Cano-Soldado, Ignacio M. Larráyoz, Míriam Molina-Arcas, F. Javier Casado, Javier Martinez-Picado, M. Pilar Lostao, Marçal Pastor-Anglada

    Research output: Contribution to journalArticleResearchpeer-review

    36 Citations (Scopus)

    Abstract

    Human concentrative nucleoside transporter-1 (hCNT1) (SLC28A1) is a widely expressed, high-affinity, pyrimidine-preferring, nucleoside transporter implicated in the uptake of naturally occurring pyrimidine nucleosides as well as a variety of derivatives used in anticancer treatment. Its putative role in the uptake of other pyrimidine nucleoside analogues with antiviral properties has not been studied in detail to date. Here, using a hCNT1 stably transfected cell line and the two-electrode voltage-clamp technique, we have assessed the interaction of selected pyrimidine-based antiviral drugs, inhibitors of HIV-1 reverse transcriptase such as zidovudine (AZT), stavudine (d4T), lamivudine (3TC) and zalcitabine (ddC), with hCNT1. hCNT1 transports AZT and d4T with low affinity, whereas 3TC and ddC are not translocated, the latter being able to bind the transporter protein. Selectivity appears to rely mostly upon the presence of a hydroxyl group in the 3′-position of the ribose ring. Thus, hCNT1 cannot be considered a broad-selectivity pyrimidine nucleoside carrier; in fact, very slight changes in substrate structure provoke a dramatic shift in selectivity.
    Original languageEnglish
    Pages (from-to)993-1002
    JournalAntiviral Therapy
    Volume9
    Issue number6
    Publication statusPublished - 1 Dec 2004

    Fingerprint Dive into the research topics of 'Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1)'. Together they form a unique fingerprint.

    Cite this